Literature DB >> 15140787

Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEF.

C Fiehn, E Rochel, A D Ho, R Max.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15140787      PMCID： PMC1755026          DOI： 10.1136/ard.2003.014217

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

1.  Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.

Authors:  Vivien Chan; Bruce G Charles; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

2.  Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.

Authors:  E N van Roon; T L T A Jansen; M A F J van de Laar; M Janssen; J P Yska; R Keuper; P M Houtman; J R B J Brouwers
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

3.  Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone.

Authors:  C Fiehn; S Jacki; B Heilig; M Lampe; G Wiesmüller; C Richter; E Röther; E Rochel; I Gao
Journal:  Rheumatol Int       Date:  2007-04-12       Impact factor: 3.580
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.